2023 World Conference on Lung Cancer (Posters)-EP11.03. Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens

EP11.03. Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens - PDF(Abstract)

Back to course

Pdf Summary

This study examined the long-term outcomes and toxicities in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunotherapy or chemotherapy-immunotherapy. The researchers conducted a retrospective observational study of 190 patients treated between January 2014 and December 2020. Of these patients, 32 (17%) were identified as long-term responders, defined as having an ongoing response at 2 years post-treatment. <br /><br />The majority of the long-term responders had a good performance status and high levels of PD-L1 expression, indicating a more favorable prognosis. The median duration of treatment was 23 months, and 16% of patients prematurely ceased treatment. <br /><br />The rate of disease progression was 31% at a median follow-up of 39 months, and there was no significant difference in progression rates based on treatment completion or PD-L1 expression. Three-year progression-free survival (PFS) was 78%, with a trend towards improved PFS in patients with high PD-L1 expression. Three-year overall survival (OS) was 96.6%, and there were no significant differences in OS between subgroups.<br /><br />The most common type of disease progression was oligo-progression, with lung or pleural disease being the most common sites of progression. Patients with disease progression were usually treated with local therapy alone or in combination with systemic therapy.<br /><br />Nearly 70% of patients experienced toxicity during treatment, with endocrinopathies being the most common, including thyroiditis, hypophysitis, and diabetes. These patients required long-term hormone replacement therapy. Other ongoing toxicities included skin toxicity and arthritis.<br /><br />Overall, the long-term responders had good outcomes, with high rates of PFS and OS. Treatment completion or premature cessation did not significantly impact survival outcomes. However, almost half of the patients experienced long-term toxicities, primarily endocrinopathies, requiring ongoing intervention. These findings have implications for patient discussions, surveillance, and long-term management.

Asset Subtitle

Meghana Maddula

Meta Tag

Speaker Meghana Maddula

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

metastatic non-small cell lung cancer

immunotherapy

chemotherapy-immunotherapy

long-term outcomes

toxicities

retrospective observational study

long-term responders

PD-L1 expression

disease progression

endocrinopathies